Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double Blind, Placebo (Vehicle) and Standard Care Controlled, Randomised, Parallel Group Study to Investigate the Clinical Safety, Toleration, Systemic Pharmacokinetics and Local Pharmacodynamics of Repeated, Escalating Concentrations of Intradermal RN1001 in Healthy Male Subjects.

NCT00978302 is registered in ClinicalTrials.gov with Renovo as lead sponsor.

NCT NCT00978302
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00978302 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double Blind, Placebo (Vehicle) and Standard Care Controlled, Randomised, Parallel Group Study to Investigate the Clinical Safety, Toleration, Systemic Pharmacokinetics and Local Pharmacodynamics of Repeated, Escalating Concentrations of Intradermal RN1001 in Healthy Male Subjects.
Lead sponsor
Renovo
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2001
Completion date
August 31, 2001
Enrollment
55 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cicatrix, wound healing